Trial Profile
Phase ll trial of TS-1 + CDDP + Trastuzumab(SPT)-3 weekly schedule in HER2-positive advanced gastric cancer(HERBIS-1) (OGSG 1101)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2022
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Cisplatin; Trastuzumab
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms HERBIS-1
- 17 Dec 2014 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 07 Dec 2012 Planned End Date changed from 1 Jun 2015 to 31 May 2014 as reported by University Hospital Medical Information Network - Japan.
- 26 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.